Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis.

Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis.
复制标题

DOI:
10.3109/17482968.2010.522586
复制
发表时间:
2011-03
期刊:
Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases
影响因子:
--
通讯作者:
Kirsch DR
Kirsch DR
中科院分区:
其他
文献类型:
--
作者:
Benmohamed R;Arvanites AC;Kim J;Ferrante RJ;Silverman RB;Morimoto RI;Kirsch DR

文献摘要

参考文献

被引文献

相似文献

肌萎缩侧索硬化症(ALS)是一种进行性神经退行性疾病,其根本原因尚不清楚。然而,有强有力的证据表明,一种病理生理机制,毒性蛋白质错误折叠和/或聚集,可能会引发运动神经元功能障碍和损失。由于散发性和家族性ALS的临床和病理特征难以区分,因此可以通过研究表达突变形式的SOD 1的模型中的发病机制和治疗来更好地理解并最终治疗所有形式的疾病。我们开发了一种细胞模型,其中细胞死亡依赖于G93 A SOD 1的表达,G93 A SOD 1是在家族性ALS患者中发现的超氧化物歧化酶的突变形式,其产生毒性蛋白质聚集体。该细胞模型被优化用于高通量筛选,以从> 50,000个成员的化学文库中鉴定保护性化合物。在筛选实施、反筛选和二次测试之后,选择三种新型化学支架用于进一步研究,包括使用购买的类似物的研究。在高含量筛选试验中,所有三种支架均阻断了SOD 1聚集,将分别报告这些化合物的优化和进一步表征数据。这些数据表明,这些化学品支架的优化可能会产生ALS患者的治疗候选人。
The underlying cause of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disorder, remains unknown. However, there is strong evidence that one pathophysiological mechanism, toxic protein misfolding and/or aggregation, may trigger motor neuron dysfunction and loss. Since the clinical and pathological features of sporadic and familial ALS are indistinguishable, all forms of the disease may be better understood and ultimately treated by studying pathogenesis and therapy in models expressing mutant forms of SOD1. We developed a cellular model in which cell death depended on the expression of G93A SOD1, a mutant form of superoxide dismutase found in familial ALS patients that produces toxic protein aggregates. This cellular model was optimized for high throughput screening to identify protective compounds from a >50,000-member chemical library. Three novel chemical scaffolds were selected for further study following screen implementation, counter-screening and secondary testing, including studies with purchased analogs. All three scaffolds blocked SOD1 aggregation in high content screening assays and data on the optimization and further characterization of these compounds will be reported separately. These data suggest that optimization of these chemicals scaffolds may produce therapeutic candidates for ALS patients.
DOI: 10.1126/science.1166066
发表时间: 2009-02-27
期刊: SCIENCE
影响因子: 56.9
作者:
Kwiatkowski, T. J., Jr.;Bosco, D. A.;Brown, R. H., Jr.
通讯作者: Brown, R. H., Jr.
TDP43 是一种人类低分子量神经丝蛋白(hNFL)mRNA 结合蛋白
DOI: 10.1016/j.mcn.2007.03.007
发表时间: 2007-06-01
影响因子: 3.5
作者:
Strong, Michael J.;Volkening, Kathryn;Shoesmith, Christen
通讯作者: Shoesmith, Christen
DOI: 10.1073/pnas.0902505106
发表时间: 2009-05-12
影响因子: 11.1
作者:
Karch, Celeste M.;Prudencio, Mercedes;Borchelt, David R.
通讯作者: Borchelt, David R.
DOI: 10.1074/jbc.m509201200
发表时间: 2006-02-17
影响因子: 4.8
作者:
Matsumoto, G;Kim, S;Morimoto, RI
通讯作者: Morimoto, RI
DOI: 10.1126/science.1165942
发表时间: 2009-02-27
期刊: Science (New York, N.Y.)
影响因子: --
作者:
Vance C;Rogelj B;Hortobágyi T;De Vos KJ;Nishimura AL;Sreedharan J;Hu X;Smith B;Ruddy D;Wright P;Ganesalingam J;Williams KL;Tripathi V;Al-Saraj S;Al-Chalabi A;Leigh PN;Blair IP;Nicholson G;de Belleroche J;Gallo JM;Miller CC;Shaw CE
通讯作者: Shaw CE